Skip to main content
Premium Trial:

Request an Annual Quote

NIPD Genetics Raises €2.5M to Fund Development of Noninvasive Down Syndrome Dx


NIPD Genetics, an early-stage Cypriot molecular diagnostics firm, said last week that it has raised €2.5 million (about $3.36 million) and moved into a new facility to support the planned commercialization of its noninvasive prenatal diagnostic test for Down syndrome.

The company, an October 2010 spinoff of the non-profit Cyprus Institute of Neurology and Genetics, developed its test based on the research of CING scientist Philippos Patsalis.

The test combines a technique called methylated DNA immunoprecipitation, or MeDiP, with qRT-PCR. More specifically, MeDiP uses an antibody specific for 5-methylcytidine to capture methylated sites and enrich for hypermethylated fetal and hypomethylated maternal DNA regions.

Following methylation enrichment of the fetal DNA in maternal circulation, the researchers apply qRT-PCR to quantify the amount of fetal DNA in the test sample. By comparing the amount of fetal DNA present in an unknown sample to that of a control sample from a pregnant woman with a normal fetus, the technique can quantify the extra copy of chromosome 21 and distinguish Down syndrome pregnancies from normal pregnancies.

In March, Patsalis and colleagues published a paper in Nature Medicine demonstrating that the assay can diagnose Down syndrome with 100 percent sensitivity and specificity. They also provided preliminary evidence that their method is simpler, faster, and cheaper than other noninvasive methods for diagnosing the condition (PCR Insider, 3/10/11).

At the time, Patsalis told PCR Insider that NIPD Genetics hoped to commercialize its test within two years. Last week, the company disclosed that it successfully raised €2.5 million from both listed and privately held funds as well as private investors.

The company said that it plans to use these proceeds to fund continued research and development and subsequent international commercialization of the Down syndrome test as well as other noninvasive tests for genetic disorders, though it didn't specify which ones.

Also, NIPD said that in July it appointed a new board of directors; and at the start of this month it has moved to new premises in Cyprus with specialized laboratories, administrative offices, and production facilities.

NIPD has also filed a provisional patent application with the US Patent and Trademark Office for its method and test.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.